Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma

Japanese Journal of Urology

Volumn 87, Issue 7, 1996, Pages 997-1003

  Kakinuma, Hideaki ^a   Sasaki, Ryusei ^a   Sato, Kazunari ^a   Hirano, Shigeru ^d   Miura, Kunio ^b   Sasaki, Shuhei ^c   Kato, Tetsuro ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA RED CROSS HOSPITAL   (Japan)

^c Akita City Hospital   (Japan)

^d Iwate Prefectural Isawa Hospital   (Japan)

Author keywords

hormone therapy; prognosis; prostate carcinoma; prostate specific antigen

Indexed keywords

FOSFESTROL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CARCINOMA; TRANSURETHRAL RESECTION;

EID: 0029810693     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.87.997     Document Type: Article

References (21)

1. Kuriyama, M.: Prostate-specific antigen as a tumor marker in prostate cancer. Int. J. Urol., 1, 99-113, 1994.
2. Oesterling, J.E.: Prostate specific antigen: A critical assessment of the most useful tumor maker for adenocarcinoma of the prostate J. Urol., 145, 907-923, 1991.
3. Schmid, H.P., McNeal, J.E and Stamey, T.A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increaseing cancer volume. Cancer, 71, 2031-2040, 1993.
4. Zagars, G.K. and Pollack, A.: The fall and rise of prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer, 72, 832-842, 1993.
5. Benson, M.C., Whang, I.S., Pantuck, A., Ring, K., Kaplan, S.A., Olsson, C.A and Cooner, W. H.: Prostate specific antigen density. A means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol., 147, 815-816, 1992.
6. Miller, J.I., Ahmann, F R., Drach, G.W., Emerson, S.S. and Bottaccini, M.R.: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 147, 956-961, 1992.
7. Fowler, J.E., Pandey, P., Seaver, L.E., Feliz, T. P. and Braswell, N.T.: Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J. Urol., 153, 1860-1865, 1995.
8. Matzkin, H., Eber, P., Todd, B., Zwaag, R. and Soloway, M.S.: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer, 70, 2302-2309, 1992.
9. Arai, Y., Yoshiki, T. and Yoshida, O.: Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J. Urol., 144, 1415-1419, 1990.
10. Stamey, T.A., Kabalin, J.N., Ferrari, M. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV anti-androgen treated patients. J. Urol., 141, 1088-1090, 1989.
11. Ernst, D.S., Hanson, J., Venner, P.M. and Urooncology group of Northern Alberta: Analysis of prognostic factors in men with metastatic prostate cancer. J. Urol., 146, 372-376, 1991.
12. Matzkin, H., Perito, P.E. and Soloway, M.S.: Prognostic factors in metastatic prostate cancer. Cancer, 72, 3788-3792, 1993.
13. Fossa, S.D., Waehre, H. and Paus, E.: The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. Br. J. Cancer, 66, 181-184, 1992.
14. Stamey, T.A., Ferrari, M.K. and Schmid, H.P.: The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J. Urol., 150, 1856-1859, 1993.
15. Stamey, T.A. and Kabalin, J.N.. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J. Urol., 141, 1070-1075, 1989.
16. Akakura, K., Bruchovsky, N., Goldenberg, S.L., Rennie, P.S., Buckley, A. and Sullivian, L.D.: Effects of intermittent androgen suppression on androgen-dependent tumor. Apotosis and serum prostate-specific antigen. Cancer, 71, 2782-2790, 1993.
17. Bruchovosky, N., Rennie, P.S., Coldman, A.J., Goldenberg, S.L., To, M. and Lawson, D.: Effects of androgen withdrawal on the stem cell composition of the shionogi carcinoma. Cancer Res., 50, 2275-2282, 1990.
18. Landstrom, M., Damber, J.E. and Bergh, A.: Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apototic cell death rate Cancer Res., 54, 4281-4284, 1994.
19. Leo, M.E., Bilhartz, D.L., Bergstralh, E.J. and Oesterling, J.E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J. Urol., 145, 802-806, 1991.
20. Isaacs, J.T. and Coffey, D.S : Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res., 41, 5070 -5075, 1981.